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Background: Current data suggest that an efficacious human immunodeficiency virus type 1 (HIV-1) vaccine
should elicit both adaptive humoral and cell mediated immune responses. Such a vaccine will also need to protect
against infection from a range of heterologous viral variants. Here we have developed a simian-human
immunodeficiency virus (SHIV) based model in cynomolgus macaques to investigate the breadth of protection
conferred by HIV-1W61D recombinant gp120 vaccination against SHIVsbg and SHIVSF33 challenge, and to identify
correlates of protection.
Results: High titres of anti-envelope antibodies were detected in all vaccinees. The antibodies reacted with both
the homologous HIV-1W61D and heterologous HIV-1IIIB envelope rgp120 which has an identical sequence to the
SHIVsbg challenge virus. Significant titres of virus neutralising antibodies were detected against SHIVW61D expressing
an envelope homologous with the vaccine, but only limited cross neutralisation against SHIVsbg, SHIV-4 and
SHIVSF33 was observed. Protection against SHIVsbg infection was observed in vaccinated animals but none was
observed against SHIVSF33 challenge. Transfer of immune sera from vaccinated macaques to naive recipients did not
confer protection against SHIVsbg challenge. In a follow-up study, T cell proliferative responses detected after
immunisation with the same vaccine against a single peptide present in the second conserved region 2 of HIV-1 W61D
and HIV-1 IIIB gp120, but not SF33 gp120.
Conclusions: Following extended vaccination with a HIV-1 rgp120 vaccine, protection was observed against
heterologous virus challenge with SHIVsbg, but not SHIVSF33. Protection did not correlate with serological responses
generated by vaccination, but might be associated with T cell proliferative responses against an epitope in the second
constant region of HIV-1 gp120. Broader protection may be obtained with recombinant HIV-1 envelope based vaccines
formulated with adjuvants that generate proliferative T cell responses in addition to broadly neutralising antibodies.
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In spite of significant efforts to make effective anti-
retroviral therapies available to HIV-1 infected individuals,
the development of an effective vaccine must be considered
a priority that is likely to be the best hope for reducing the
spread of HIV infection [1–3]. Recombinant HIV-1 enve-
lope based AIDS vaccines have progressed to phase 3 trials
[4–6] but they failed to demonstrate any evidence that the
vaccine formulations tested (bivalent gp120 envelope anti-
gen adjuvanted with Alum (AIDSVAXW B/E) were able to
prevent acquisition of infection. However, in a recent phase
3 trial, where the AIDVAX B/E vaccine was used in prime-
boost regimen with the canarypox ALVAC-HIV vCP1521
vaccine, modest efficacy against HIV-1 acquisition was
demonstrated [7]. It is believed that a central problem with
these vaccine formulations is that antibodies elicited are fo-
cused on the hypervariable regions of the envelope protein
of HIV-1 which limits their ability to neutralise viruses
expressing heterologous envelopes. Therefore, it is essential
that we identify adaptive immune responses elicited by vac-
cination that have the potential to increase the breadth of
protection with HIV-1 envelope based vaccines.
The experimental infection of macaques with defined
SIV/HIV-1 (SHIV) chimeric viruses provides a model to
establish the breadth of protection of candidate vaccines
and characterise the key vaccine responses that correlate
with the protection observed in a highly controlled man-
ner which cannot be done readily in clinical trials [8]. In
previous reports, we have utilised SHIV’s to study the pro-
tection conferred by HIV-1W61D r (recombinant) gp120
formulated in a potent adjuvant in the macaque model.
Three immunisations with HIV-1W61D rgp120 in SBN1
adjuvant did not protect against challenge with heterol-
ogous SHIVSF33 that exhibits 85% amino acid identity
across rgp120 [9]. Mooij et al. [10] reported however, that
5 immunisations with this vaccine protected macaques
against detectable infection following challenge with the
homologous SHIVW61D [11]. Furthermore, following an
additional single boost of HIV-1W61D rgp120 [12], these
same animals were protected against challenge with heter-
ologous SHIVSF13 and SHIVHAN-2 that shared overall 88%
[13] and 82% [14] amino acid identity respectively across
rgp120. A further single immunisation was given to these
animals and challenged with a pathogenic SHIV89.6P, but
only one of the vaccinees was protected. In another study,
Voss and colleagues [15] reported that whilst immunisa-
tion with AS02A–adjuvanted HIV-1W61D rgp120 did not
prevent SHIV89.6p infection, it did prevent CD4+ cell de-
cline and delayed the onset of AIDS. Thus, whilst protec-
tion against heterologous SHIV challenge is possible, the
factors that conferred protection against selected heterol-
ogous SHIVs are poorly understood. Neutralising anti-
bodies are associated with protection against homologous
[16] and heterologous SHIV challenge [17]. However,Ellenberger et al. [18] could not determine an immune
correlate of the protection conferred by a multi-protein
DNA/MVA HIV-1 vaccine in rhesus monkeys against a
highly heterologous SHIVSF162P3. Recent studies have
also questioned the role of neutralising antibodies alone,
since vaccine protection was observed against neutralising
antibody resistant virus challenge [19] and with persist-
ence of T cell responses [20].
This report investigates the potential of an extended
immunisation protocol using the AS02A–adjuvanted
HIV-1W61D envelope vaccine to protect against heterol-
ogous SHIV challenges. Although protection against
SHIVSF33 acquisition was not elicited by this vaccine
regimen, SHIVsbg challenge was resisted in the absence of
detectable cross-neutralising antibodies. Furthermore, pro-
tection against SHIVsbg was not transferred with immune
serum. Since there is no evidence that this vaccine elicits
CD8+ T cells responses, these observations raise the possi-
bility that CD4+ T cells may be involved in the protection
observed. Analysis of the CD4+ T cell responses elicited by
this vaccine indicates that reactivity to a peptide in the C
(constant) region 2 of HIV-1 gp120 hints at an association
with the protection observed against SHIV challenge. Fur-
ther studies using the SHIV/macaque model could establish
whether these CD4+ cell responses to vaccination might
provide effective anti-viral immunity directly.
Results
Antibody responses following immunisation with
HIV-1W61D rgp120
Eight macaques (A71-A78) were immunised with the
vaccine and then split into two groups of four for subse-
quent challenge with either SHIVsbg (group A; Table 1)
or SHIVSF33 (group B; Table 1). All vaccinees serocon-
verted to HIV-1W61D rgp120 as determined by ELISA
following the second immunisation. Two weeks after the
third immunisation, the mean log10 end point titre was
4.28+/−0.17. Five subsequent boosts failed to increase
binding titres. On the day of challenge the mean log10
end point titre was 4.03+/−0.15.
To determine whether immunisation with HIV-1W61D
rgp120 elicited antibodies that cross react with the
SHIVsbg challenge virus, ELISAs were carried out using
HIV-1IIIB rgp120 (CFAR EVA607), since this isolate has
an identical envelope sequence [21]. ELISA could not be
performed against SHIVSF33 due to the lack of availabil-
ity of SF33 rgp120.
Sera collected from all vaccinees were tested for their
ability to neutralise homologous virus (SHIVW61D) and
heterologous challenge viruses (SHIVsbg and SHIVSF33).
All vaccinees developed moderate titres (50% log 10 titre
>2.3) of neutralising antibodies against the homologous
SHIVW61D at either the day of challenge (group A) or
after 7 immunisations (group B) (Table 2).
Table 1 Immunisation schedule
Group Animal numbers Vaccine Schedule (weeks) Challenge virus
A A71, A75, A76, A78 W61D rgp120+ AS02A 1, 4, 12, 20, 28, 36, 44, 86 SHIVsbg
a
B A72, A73, A74, A77 W61D rgp120+ AS02A 1, 4, 12, 20, 28, 36, 44, 92 SHIVSF33
b
C B234-B237 AS02A SHIVsbg
c
D B238-B241 AS02A SHIVSF33
d
E C37-C40 Serum transfer SHIVsbg
e
F C41-C44 None SHIVsbg
f
G G19; G21 W61D rgp120+ AS02A 1, 4, 8 None
a = 10 MID50 SHIVsbg challenge dose + 4 weeks after last immunisation.
b = 50 MID50 SHIVsbg challenge dose + 4 weeks after last immunisation.
c = 10MID50 challenge dose contemporaneous with group A.
d = 50MID50 challenge dose contemporaneous with group B.
e = 50MID50 challenge dose given 24 hours following serum transfer.
f = 50MID50 contemporaneous with group F.
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(group A) and infected (group C) naive control sera using
both single cell infectivity and T cell line based neutralisa-
tion assays (Table 2). We also tested the ability of the sera
to neutralise SHIV-4 [22], which has an identical envelope
sequence to SHIVsbg, to examine whether the lack of neu-
tralisation was a specific feature of the challenge virus.
Very low titre (50% log 10 titre <1.6) neutralising activity
was observed in the vaccinees of group A and B against



























a = time of sampling.Low titres (50% log 10 titre; range 1.5-1.6) of SHIVSF33
neutralisation were detected in group B vaccinees after 7
immunisations (Table 2). In infected controls (group D)
at termination of the study higher titres (50% log 10 titre;
range 2.4-2.7) were observed (Table 2).
Immunisation protects against challenge with
heterologous SHIVsbg
Four weeks after the 8th immunisation, group A was chal-
lenged intravenously with 10 MID50 SHIVsbg along with 4IV-1W61D rgp120
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Table 3 Detection of virus following challenge with heterologous SHIVsbg (10 MID50 dose)
GROUP ID
NO.
VACCINE OUTCOME OF CHALLENGE
(Weeks Post Challenge)
−4 2 4 8 12 16 20
VI VT* PCR VI PCR PCR VI PCR VI
A A71 30 μg W61D rgp120/AS02A i.m - <0.5 - - - - - - -
A75 - <0.5 - - - - - - -
A76 - <0.5 - - - - - - -
A78 - <0.5 - - - - - - -
C B234 AS02A i.m - <0.5 - - - - - - -
B235 - 1.5 + + + + - - -
B236 - 3.0 + + + + - + -
B237 - 3.0 + + + + + - -
VT* = Virus Titration; Number of SIV + ve cells per 106 PBMC.
VI = Virus isolation by co-culture of 5 x 106 PBMC with 105 C8166 indicator cells.
PCR =Diagnostic DNA PCR specific for SIV gag.
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lowing challenge, three of the controls became persistently
infected with virus as determined by detection of proviral
DNA, recovery of virus by co-culture (Table 3) and detec-
tion of viral RNA in plasma (Figure 1). Peak viral loads at
2 weeks were 5.3 +/− 0.6 mean log10 titre. By contrast, there
was no evidence of detectable infection of the 4 vaccinees at
any time point analysed after challenge (Table 3; Figure 1).
Transfer of immune serum does not protect naïve
macaques against challenge with SHIVsbg
Serum collected from the 8 vaccinees (group A and B;
A71-A78) that received the same vaccine protocol onFigure 1 Viral RNA levels in vaccinated macaques (A71, A75, A76 and
ASO2A adjuvant only (B234-237; group C: red lines) after challenge wmultiple occasions between the 3rd and 8th immunisations
with HIV-1W61D rgp120 was pooled and 25ml/kg trans-
ferred into each of 4 naïve macaques (group E; C37-C40;
Table 1). Twenty four hours later, they were challenged
intravenously with 50 MID50 SHIVsbg along with 4 naïve
controls (group F: C41-44: Table 1). At the time of chal-
lenge, binding antibodies against HIV-1W61D rgp120
(mean log10 titre 4.05+/−0.19) and HIV-1 IIIB rgp120
(mean log10 titre 3.75+/− 0.17; Table 4) were detectable in
the recipients. In addition, neutralising activity against
the homologous SHIVW61D (mean log10 titre 2.4+/− 0.06)
but not against the challenge virus SHIVsbg (Table 4) was
detected in these individuals. At 2 weeks after challenge,A78; group A: blue lines) and contemporaneous controls given
ith 10MID50 SHIVsbg and followed for twenty weeks.








(50% virus inhibition log 10 titre) DOCa
W61D rgp120 IIIB rgp120 SHIVW61D SHIVsbg
E C37 Serum from group A 3.9 3.9 2.4 <1
C38 3.9 3.9 2.4 <1
C39 4.3 3.6 2.5 <1
C40 4.1 3.6 2.5 <1
DOC=day of challenge.
a = time of sampling.
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recipients of immune serum (Table 5). The peak vRNA
loads at 2 weeks in naïve challenge controls (log10 4.70
+/− 0.49) were not significantly different from recipients
of immune serum (log10 4.51+/0.84; Figure 2). Further-
more, the persistence of virus in blood, assessed by virus
recovery and DNA PCR, was similar for the two groups of
macaques (Table 5).
Immunisation with HIV-1W61D rgp120 does not protect
against SHIVSF33 challenge
Four weeks after the final (8th) immunisation, macaques
in group B were challenged intravenously with SHIVSF33
[12] (Table 1). After challenge, SHIVSF33 was detected in
all the vaccinated macaques (A72, A73, A74, A77) at
2 weeks by DNA PCR and/or RT-PCR of plasma (Table 6).
It was also possible to re-isolate virus by co-culture of
PBMC with C8166 indicator cells from all 4 vaccinated
macaques 4 weeks after challenge (Table 6). From 8 weeks
to 20 weeks, detection of virus in the blood became more
sporadic.Table 5 Detection of virus following transfer of immune serum












VT* = Virus Titration; Number of SIV + ve cells per 106 PBMC.
VI = Virus isolation by co-culture of 5 x 106 PBMC with 105 C8166 indicator cells.
PCR =Diagnostic DNA PCR specific for SIV gag.
ND=Assay not performed.At 2 weeks after challenge the log10 mean viral load
(4.23± 0.94) in vaccinees was not significantly different
from unvaccinated controls (5.3 ± 0.62; Figure 3). Max-
imal vRNA loads were detected in plasma of vaccinees
at 2 weeks. The vRNA levels declined thereafter to un-
detectable levels at week 12. At 2 and 8 weeks after chal-
lenge, animal A74 alone was negative by DNA PCR but
became positive at week 12. All vaccinees were found to
be positive by virus co-culture assay at 4 weeks but at
12 weeks only two macaques (A74 and A77) were posi-
tive. At 20 weeks, virus or vRNA could not be recovered
from any vaccinee.
All of the unvaccinated controls (group D: Table 1) be-
came infected by 4 weeks by virus co-culture assay and
therefore mirrored the situation observed for the vacci-
nees (Table 6). No virus was detected within this group at
20 weeks after challenge by co-culture. All controls were
positive by DNA PCR at 12 weeks. The vRNA levels also
showed a similar profile to that of the vaccinees with a
peak viraemia at 2 weeks followed by a decline to un-
detectable levels by 20 weeks in all animals (Figure 3).from W61D rgp120 immunised macaques and
OUTCOME OF CHALLENGE
(Weeks Post Challenge)
−2 2 4 9 10 20
VI VI VT* PCR PCR VI VI VI
ay −1 - + 2.5 - + + ND -
- + 2.0 + + + ND +
- + 2.0 + + + ND -
- + 1.5 + + + ND -
- ND 2.5 + + ND - -
- ND 1.0 - + ND - -
- ND 3.0 + + ND - -
- ND 3.0 + + ND + -
Figure 2 Viral RNA levels in macaques given immune serum (C37-40; group E: blue lines) and contemporaneous controls (C41-44;
group F: red lines) after challenge with 50MID50 SHIVsbg and followed for twenty weeks.
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The results of MHC typing of cynomolgus macaque in
groups A, B and C are shown in figure 4. Whilst one ma-
caque in each of groups A, B and C is homozygous for
M2, M1 and M3 haplotypes, respectively, the remaining
macaques were simple heterozygotes or possessed a sim-
ple recombination across MHC class I haplotypes. Across
MHC class II haplotypes macaque A71 in group A was a
match for B235 and B237 in group C whereas macaque
A75 in group A was a match for A73 in group B. In a fol-
low up study to analyse CD4+ T cell responses macaque















VI = Virus isolation by co-culture of 5 x 106 PBMC with 105 C8166 indicator cells.
PCR =Diagnostic DNA PCR specific for SIV gag.
ND=Assay not performed.was heterozygous for M1/M4, were selected as they were
MHC haplotype matches for group A macaques A76 and
A71, respectively.
Immunisation with HIV-1W61D rgp120 elicits potent T cell
proliferative responses
In the initial challenge studies, insufficient samples were
taken for analysis of cell-mediated immunity as we believed
that protection would be antibody mediated as per homolo-
gous protection. When this proved not to be the case for
heterologous protection, a retrospective study was under-
taken to analyse cell-mediated immune responses. For thisous SHIVSF33 (50 MID50 dose)
OUTCOME OF CHALLENGE
(Weeks Post Challenge)
2 4 8 12 20
PCR VI VI PCR VI PCR VI
+ + ND + - + -
+ + ND + - + -
- + ND - + + -
+ + ND + + + -
+ + - + - + -
+ + - + - + -
- + - + - + -
+ + - - + + -
Figure 3 Viral RNA levels in vaccinated macaques (A72, A73, A74 and A78; group B: blue lines) and contemporaneous controls given
ASO2A adjuvant only (B238-241; group D: red lines) after challenge with 50MID50 SHIVSF33 and followed for twenty weeks.
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table 1), that were MHC matched with two animals from
group A vaccinees, A76 (M1/M3 haplotype) and A71
(M1/M4 haplotype) respectively, which had resisted
SHIVsbg challenge (table 3, figure 4).
For analysis of T cell proliferative responses, peptides
pools were selected on the basis of sequence homology
of at least 9 consecutive amino acid residues, sufficient
to constitute a shared T cell epitope, between W61D
and IIIB or SF33 HIV-1 envelope sequences. Hereafter,
homology is referred to in terms of potential shared T
cell epitopes. Peptides across variable loops 1, 2, 3 and 4
showed little homology between W61D, IIIB and SF33
sequences and were divided into 3 pools that approxi-
mately covered V1/V2, V3 and V4 regions for each enve-
lope sequence (Table 7). Five peptides across C1 and
two within C2 that showed homology between W61D,
IIIB and SF33 sequences formed the C1 peptide pool
(Table 7). Four further peptides within C2 that showed
homology between W61D and IIIB but not SF33 formed
the C2 pool and this was compared with the corre-
sponding SF33 C2 pool (Table 7). These four C2 pep-
tides with W61D/IIIB homology were tested individually
against corresponding SF33 C2 peptides (Table 7). Two
peptides across C3 showed homology between W61D
and SF33 but not IIIB formed the C3 pool (Table 7).
All proliferative T cell responses detected against pep-
tide pools were mostly (>90%) CD4+ T cell responses(data not shown). G19 made a broad proliferative T cell
response that was significant against W61D V1/V2, V3
and V4 peptide pools, compared with corresponding
SF33 peptide pools (Figure 5A). By contrast, the G21 re-
sponse was strongly focused on and highly significant
for the V4 peptide pool (figure 5A). Responses against
IIIB and SF33 V1/V2, V3 and V4 peptide pools were
greatly reduced by comparison with W61D responses.
Only G19 made a proliferative response against the con-
sensus C1 peptide pool (figure 5A). Both G19 and G21
made significant proliferative responses against the C2
peptide pool compared with the corresponding SF33
peptide pool response (Figure 5B). Neither G19 nor G21
made a significant proliferative response against the C3
peptide pool (Figure 5B). When C2 peptides were tested
individually, G19 made a significant proliferative re-
sponse against all four peptides within the pool, com-
pared with the corresponding SF33 peptides, with the
strongest response directed against peptide ARP7035.19
(Figure 5B; Additional file 1: Table S1). G21 made sig-
nificant proliferative responses against two of the four
peptides within the C2 pool, compared with the corre-
sponding SF33 peptides. The strongest response was
also directed against peptide ARP7035.19 (Figure 5B;
Table S1). G21 also made a significant proliferative re-
sponse against ARP7035.18, which overlaps ARP7035.19
by 10 amino acids (Figure 5B; Table S1). Comparison of
sequences across the region covered by peptide ARP7035.19
Table 7 Composition of HIV-1 envelope peptide pools tested
Peptide Pools W61D IIIB SF33
V1/V2 Pool ARP7035.6-17 ARP740.6-16 ARP7117.6-16
V3 Pool ARP7035.22, 25-33 ARP740.21, 24-33 ARP7117.21, 24-33
V4 Pool ARP7035.34-38, 41-48 ARP740.33-38, 41-47 ARP7117.33-38,41-46
C1 Pool ARP7035.1-5, 20, 21 nt nt
C2 Pool ARP7035.18, 19, 23, 24 nt ARP7117.17, 18, 22, 23
C3 Pool ARP7035.39, 40 nt nt
nt = not tested.
20mer HIV-1 env gp120 peptides with 10mer overlap from CFAR, NIBSC, UK.
A71 A75 A76 A78
Class I A
M1 M4 M1 M2 M1 M3 M2 M2
Class I B
M1 M4 M1 M2 M1 M3 M2 M2
Class II
M1 M4 M1 M2 M1 M3 M2 M2
A72 A73 A74 A77
Class I A
M1 M5 M1 REC M1 M1 M3 M4
Class I B
M1 M5 M1 M5 M1 M1 M3 M5
Class II
M1 M5 M1 M2 M1 M1 M3 M5
732B632B532B432B
Class I A
M5 M3 M1 M1 M3 M3 M1 M4
Class I B
M5 REC M1 M4 M3 M3 M1 M4
Class II




Key: M1 M3M2 M5M4
Figure 4 MHC haplotypes of study animals were determined by microsatellite analysis and haplotypes with recombinants resolved by
allele-specific PCR. Intact haplotypes, M1–M5, have been previously identified in Mauritian cynomolgus macaques (37, 37) are designated by
different colours (see key) for each of the animals used in groups A, B and C.
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Figure 5 Proliferative responses of HIV-1 rg120 W61D vaccinee PBMC to HIV-1 env gp120 peptide pools. Proliferation was measured by
flow cytometry using a CFSE dye dilution assay reporting the percentage of cells that have undergone at least two cell divisions. Assays were
performed in triplicate and the mean response ± SEM are shown. Responses to the vaccine isolate W61D peptide pools were compared to
heterologous IIIB and SF33 isolates. Panel A shows the response to peptide pools covering variable regions V1/V2, V3 and V4. The C1 pool
contains peptides with homology across all three isolates. The C2 pool contains peptides with homology between W61D and IIIB. The C3 pool
contains peptides with homology between W61D and SF33. Panel B compares the mean responses of the 4 peptides that comprise the C2 pool,
with homology between W61D and IIIB, with the corresponding non-homologous SF33 peptides, individually. A strong response to the W61D
peptide ARP7035.19 is common to both G19 and G21which is lost when the corresponding SF33 peptide ARP7117.18 is substituted.
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a single amino acid change at position 213 (A to T) for the
equivalent SF33 peptides ARP7117.18 that may account for
absence of a T cell response (Additional file 1: Table S1).
Discussion and Conclusions
A consensus scientific viewpoint has emerged that future
licensed AIDS vaccines should include HIV-1 envelope
protein as a component [23–25]. A recent macaque
study also highlighted the importance of including enve-
lope protein in the vaccine formulation to achieve pro-
tection from infection [19]. The challenge is to formulateenvelope based vaccines that confer broad protection
against this hypervariable viral antigen. In order to
achieve this, we need to define in detail, the protective
immune responses that envelope based vaccines need to
elicit. Whilst this information could be ascertained from
Phase 3 clinical trials, the size and cost of these trials is
such that testing in appropriate animal models is attractive,
if they are able to provide pertinent information. This
HIV-1W61D envelope component has been formulated
and tested in Phase 1 clinical trials either alone [26] or
in combination with other recombinant HIV-1 protein
antigens [27,28]. This study was designed to evaluate
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viruses that expressed a heterologous B clade HIV-1 en-
velope. We observed that protection against infection
by a chimaeric virus is feasible even in the absence of a
detectable cross neutralising antibody response against
the envelope of the challenge virus. Protection appears
to correlate with cell mediated immunity, specifically
CD4+ T cell responses against an epitope within a
conserved domain (C2) of HIV-1 gp120 (with the
caveat that this was observed in a study of only 2
animals).
In previous studies, it was shown that immunisation
with the same candidate AIDS vaccine based upon HIV-1
W61D rgp120 formulated in AS02A adjuvant protects
macaques against intravenous challenge with SHIVW61D
expressing the homologous envelope [10] and that im-
mune serum collected from immunised macaques could
transfer this protection (Almond et al., manuscript in
prep). In previous observations, increasing the number of
vaccinations above three doses enhanced the neutralising
antibody titres whilst the binding antibody titres remained
constant (Almond et al., manuscript in prep). This sug-
gests that the additional immunisations result in qualita-
tive changes in the neutralising antibody responses. These
responses appeared to be focussed primarily against vari-
able regions of the envelope, therefore limiting the poten-
tial breadth of protection. In our initial study designed
to interrogate the breadth of protection possible with
HIV-1 envelope based vaccines, no cross protection was
observed, when a three dose vaccine schedule had been
employed [9]. However, other studies have indicated that
protection against heterologous SHIV was possible, when
the heterologous SHIV challenge occurred as a follow
up after vaccine recipients had resisted homologous SHIV
challenge [12] (MP, NA, RS unpublished observations).
Nevertheless, there existed the possibility that the
improved breadth of protection of envelope based vac-
cines was due to exposure to other less variable viral
antigens during the initial homologous challenge, and
this led to a broadening of the protection against
heterologous viruses [12]. Our study was designed to
establish the breadth of protection after the extended
vaccine regimen without this confounding issue of
virus re-challenge.
In the first challenge study, the eight immunisation
protocol appeared to protect the vaccinees from detect-
able infection with SHIVsbg. PCR methods for virus de-
tection failed to detect any direct evidence of the viral
DNA or RNA. However, although the virus stock had
been titrated in cynomolgus macaques previously, the 10
MID50 challenge dose only infected three of four naive
challenge controls. It is unclear whether this was a result
of incorrect dilution of the virus challenge stock or a sto-
chastic event due to a probability by Poisson distributionthat a low dose inoculum will not contain a single infec-
tious agent. We have used this stock of virus in
two previous studies at this dose and have infected suc-
cessfully all of eight naive challenge controls [29]. Using
these controls there are 11/12 animals that became
infected with the 10MID50 dose compared with 0/4 vacci-
nated animals which by Fischer’s exact test returns a sta-
tistically significant difference of p = 0.003.
To investigate the role of antibody in protection, serum
from vaccinated macaques was transferred into naive reci-
pients that were then challenged with the heterologous
SHIVsbg challenge. None of these animals resisted the virus
challenge despite the serum being derived from macaques
that had resisted the same SHIV challenge. Moreover, neu-
tralising activity against the homologous virus (SHIVW61D)
in the serum remained relatively high at 2.4 log10 50% viral
inhibition titre (Table 2). These data contrast with the out-
come of our previous passive transfer studies where smaller
volumes of immune serum collected from HIV-1 rgp120
immunised macaques have protected naïve recipients even
when challenged with 10–50 MID50 of a SHIV expressing
an envelope homologous with the vaccine (MP, NA, RS un-
published observations). It is possible that the failure to
protect was due to the higher (50MID50) dose challenge
used after the serum transfer compared with the prior chal-
lenge (10MID50) after vaccination. The higher dose was
employed to ensure that all the control animals were
infected which is necessary to achieve statistical signifi-
cance. However if this 5 fold higher virus dose was suffi-
cient to overcome the saturation point of the protective
antibodies in the transferred serum then differences in the
kinetics of virus replication (such as the peak virus load) in
naive challenge controls and recipients of immune serum
may be anticipated; this was not the case (Figures 1 and 2)
as has been reported previously for SHIV challenge [30] .
Furthermore, the peak viral loads in the naive control
animals at 2 weeks receiving either the 10MID50 dose
(group C) or the 50MID50 dose (Group F) were not signifi-
cantly different (Student’s t test p=0.38).
Unlike the initial challenge with SHIVsbg, eight immuni-
sations with HIV-1W61D rgp120 did not protect against
challenge with SHIVSF33. Following challenge, the kinetics
of virus replication was not significantly different between
vaccinates and naive challenge controls. Perhaps this was
not surprising since, at the time of challenge, only very
limited cross neutralisation was detectable in the serum.
Indeed, the additional immunisations did not result in any
improvement of vaccine protection, compared with our
previous study, using this challenge virus [9].
The demonstration of protection in the absence of de-
tectable virus cross-neutralising antibodies and the lack of
protection by serum transfer suggests that other anti-HIV-1
envelope responses are required to protect against heterol-
ogous SHIV challenge. It has been reported that this
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responses in vaccine trial volunteers [27,28] and this has
been corroborated in another study in macaques (Almond
et al., manuscript in prep). We decided therefore to investi-
gate the specificity of CD4+ T cell responses using overlap-
ping HIV-1 env peptides for both vaccine and challenge
viruses to determine if there was any correlation with pro-
tection. Our rationale was that any correlate of heterol-
ogous protection must be conserved between the vaccine
and challenge virus sequence where there was protection
(SHIVsbg) and not where there was absence of protection
(SHIVSF33). Furthermore, the conserved T cell response
must be preserved in macaques with different MHC haplo-
types as all group A vaccinees were protected. Notably the
animals in this group all possessed at least one copy of the
M1, M2 or M3 haplotype; each of these haplotypes shares
common class IA alleles Mafa-A1*063:01/02, Mafa-
A2*05:01/11 and Mafa-A4*01:01, but class II allele sharing
is limited [31,32].
Analysis of CD4+ T cell proliferative responses against
variable regions of HIV-1W61D env revealed strong but
differential responses in both macaques that may be due
to their different MHC haplotypes. The M1/M3 haplo-
type of G19 appeared to favour a broad CD4+ T cell
response whilst the M1/M4 haplotype of G21 favoured a
strongly focused anti-V4 response. It could be concluded
from this result that CD4+ T cell proliferative responses
against V4 are a correlate of protection, since it is com-
mon to both challenge viruses. However as all anti-V4
responses were lost when the corresponding IIIB and
SF33 peptide pools were used to restimulate cells, then
it could not be a correlate of heterologous protection.
Similar sequence divergence between the three challenge
viruses across all variable regions prevented CD4+ cell
responses against these regions of envelope being poten-
tial correlates of vaccine protection.
By contrast, a number of peptides spanning the more
conserved regions of HIV-1 env [33] proved more interest-
ing. The highly conserved C1 region did not exhibit suffi-
cient sequence variation between the vaccine and challenge
SHIVs to account for the differential outcome of SHIVsbg
and SHIVSF33 challenges. For conserved region three, only
one of the two MHC typed macaques made detectable
CD4+ responses even against peptide based on the HIV-1
W61D envelope homologous to the vaccine. This left just
four peptides from conserved region two (C2) that were
homologous between W61D and IIIB but heterologous for
SF33. Both vaccinated macaques tested made significant
CD4+ T cell responses to peptides based on the SHIVW61D
and SHIVsbg C2 region and these were lost when the corre-
sponding peptides from SHIVSF33 were used. Although
there were differences between the precise epitope recog-
nised by each macaques studies, which is not surprising
since they were of different MHC type, both responsesmapped to a region where the sequence of SHIVsbg and
SHIVW61D envelopes are the same and distinct from
SHIVSF33.
Although it would appear unexpected that non-
antibody mediated protection elicited by HIV-1 envelope
vaccines could map to a restricted region of the conserved
region 2 of this protein covered by a region between two
and four peptides, previously published data on cross pro-
tection would appear supportive. Mooij et al. [12]
reported that, following vaccination with this or closely
related vaccine formulations of HIV-1W61D rgp120, they
observed protection against challenge with both heterol-
ogous SHIVSF13 and SHIVHAN-2. Remarkably, sequence
analysis of gp120 reveals sequence homology across the C2
region between these SHIVs and HIV-1W61D and HIV-1
IIIB (Additional file 1: Table S1). By contrast, Voss et al.
[15] reported that a closely related vaccine incorporating
the same envelope component did not protect against
SHIV89.6p infection. The envelope of SHIV89.6p exhibits
two amino acid differences across the peptide ARP7035.19
from the vaccine, although these differences are not identi-
cal to those found in SF33 (Additional file 1: Table S1).
Although we only used a 3 dose schedule for the follow
up study of 2 animals (group D) rather than an 8 dose
schedule used for the challenge studies, we predict that
this would result in a protective response against SHIVsbg
based on the study by Mooij et al. [12] where heterol-
ogous protection was observed with the same vaccine for-
mulation and a 6 dose schedule. It is likely that the cross
reactive cell mediated responses we observe after 3 immu-
nisations would still be dominant after 8 immunisations
and therefore afford protective status but there may be a
further broadening and/or maturation of responses to the
conserved regions.
Whether these preliminary observations are coincidental
is uncertain at the moment. Nevertheless, investigating
whether this apparent correlate defines a novel mechanism
of vaccine protection conferred by HIV-1 envelope vac-
cines in the absence of cross neutralising antibodies is test-
able using the Mauritian derived cynomolgus macaque
(MCM). Protection against infection in the absence of neu-
tralising antibodies has been observed for influenza [34]
and SIV [19,20]. The mechanism is likely to be through T
helper subsets, specifically effector memory cells [20] and
therefore the adjuvant (such as AS02) used in vaccine for-
mulations will be important in driving the immune re-
sponse to a protective or non-protective T helper bias; for
example in protective vaccines for malaria [35].
The limited genetic diversity at the MHC level of MCM
due to a small founder population, permits group sizes
that are immuno-genetically defined across both Class I
and Class II regions of the MHC. A more detailed analysis
of cellular immunity is therefore warranted to investigate
the response to the C2 peptide identified in this study, in
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of these groups with viruses selected by their sequence
across C2 would generate incontrovertible data whether
the CD4+ cellular responses identified in this study can
contribute to the protection in the absence of neutralising
antibodies. If so then it would open up new avenues for




Purpose bred juvenile Mauritian cynomolgus macaques
(Macaca fascicularis) obtained from a simian retrovirus
free colony, were housed and maintained in accordance
with Home Office guidelines for the care and maintenance
of primates. Animals were sedated with Ketamine before
immunisation, venepuncture or clinical examination.
Vaccination with HIV-1W61D rg120
The recombinant HIV-1W61D rgp120 antigen was engi-
neered from an envelope molecular clone derived from
the Dutch clinical HIV-1 isolate ACH320 [36] and
expressed in a mammalian expression system using Chin-
ese hamster ovary cells. The rgp120 antigen (100 μg) was
reconstituted with 0.5 ml of AS02A (GlaxoSmithKline Bio-
logicals; o/w emulsion-based Aduvant System containing
50 μg MPL and 50 μg QS21 [Antigenics, New York,
USA]) prior to vaccination. In immunisation protocols,
control animals were administered AS02A Adjuvant Sys-
tem without antigen.
A group of four macaques (group A, A71, A75, A76,
A78) was immunised intramuscularly on 8 occasions with
100 μg AS02A–adjuvanted HIV-1W61D rgp120 at 0, 4, 12,
20, 28, 36, 44 and 86 weeks. A group of four (naive) maca-
ques (group C, B234-B237) was used as challenge con-
trols. Group A was challenged with 10MID50 SHIVsbg
2 weeks after the last immunisation simultaneously with
group C animals.
Similarly, a group of four macaques (group B; A72, A73,
A74, A77) was immunised contemporaneously as for
group A. A group of naive macaques (group D; B238-241)
was used as challenge controls. Groups B and D were
challenged simultaneously with 50MID50 SHIVSF33
2 weeks after the last immunisation.
A group of two macaques (group G; G19 and G21) was
immunised with the same vaccine formulation as for
groups A and B but on 3 occasions only at 0, 4 and 8 weeks
(Table 1) for retrospective analysis of cell mediated
responses.
Serum transfer
Immune sera were collected and pooled from eight
macaques between immunisations 3 and 8 at weeks 30,
32, 35, 37, 42, 46, 48 and 50 before challenge. Four naïvemacaques (Group E; C37-C40) received 25 ml/kg of
pooled immune serum by intra-peritoneal injection.
Four controls (Group F; C41-C44), received an equiva-
lent volume of normal saline. Twenty four hours after
transfer of serum or saline, all recipients were challenge
with 50 MID50 SHIVsbg intravenously.
Heterologous SHIV challenge
The stock of SHIVsbg used throughout was as previously
described [21]. SHIVsbg was prepared on macaque PBMC
and had a titre of 1.9 x 105 MID50/ml in M. fascicularis.
The challenge dose of 10MID50 was given intravenously.
An intravenous dose of 50 MID50 was used for serum
transfer studies. SHIVSF33 [13] was grown in macaque
PBMC and had a titre of 1 x 103 MID50 in M. fascicularis
[9]. The challenge dose was 50 MID50 given intravenously.
Detection of virus following challenge
The outcome of virus challenge was evaluated for twenty
weeks after which studies were terminated. Evidence of
virus infection in the macaques after challenge was based
upon the recovery of virus either a) by co-culture of 5 x
106 Ficoll purified monocytes with C8166 indicator cells
as described previously [9] b) detection and quantification
of viral RNA in plasma following real-time qRT-PCR
mediated amplification of SIV gag sequences as described
previously [37]. The lower limit of detection of the assay is
50 SIV RNA copies/ml or c) detection of proviral DNA by
qDNA real-time PCR amplification was performed as
described previously [37].
Measurement of humoral immune responses
Binding antibodies were detected in plasma by ELISA
using recombinant HIV-1W61D rgp120 (EVA 648) and
HIV-1 IIIB (EVA607) supplied by the Centralised Facility
for AIDS Reagents (CFAR, NIBSC). Binding antibodies
were detected using goat anti-human Ig coupled to
horseradish peroxidase and end-point titre calculated as
described previously [38]. Neutralising antibody activity
was determined by a single cell infectivity assay using an
indicator cell line Tzm-Bl an adapted method of Wei
et al. [39]. The test serum was serially titrated in doub-
ling dilutions in DMEM with 10% v/v FCS in 96 well
microtitre plates in triplicate. 50 μl of 2 TCID50 concen-
tration of virus was added to all wells and the antibody/
virus mixture incubated for 45 minutes. The indicator
cell line TZM-bl which expresses β-galactosidase and
luciferase on infection with virus was added to the wells
and the plate incubated at 37 °C for 48 hours. Following
incubation, all the supernatant was aspirated and the
cells lysed with 5% NP40. An aliquot of the lysate was
transferred into an empty microtitre plate and β-gal sub-
strate added (Novagen β-red β-galactosidase kit). The
colour development was stopped with the kit stop
Page et al. Retrovirology 2012, 9:56 Page 13 of 14
http://www.retrovirology.com/content/9/1/56solution and the absorbance read at 590 nm using an
ELISA plate reader.
Viruses tested by neutralisation assay were SHIVW61D
[27], SHIV-4 [40], SHIVsbg [21] and SHIVSF33 [13].
Measurement of cell-mediated immune responses
MHC haplotypes were defined by microsatellite analysis,
with resolution of recombinant haplotypes by allele-
specific polymerase chain reaction (PCR), to report the six
most common Mauritian cynomolgus macaques MHC
haplotypes, or simple recombinants thereof as previously
described [41,42].
PBMC from immunised cynomolgus macaques G19 and
G21 group G), isolated from the heparinised blood by
Percoll density gradient separation (GE Healthcare Bio-
Sciences AB, Uppsala, Sweden), were resuspended in RPMI
1640 culture medium (Sigma-Aldrich, Poole, UK) supple-
mented with 10% foetal calf serum, L-glutamine and anti-
biotics Penicillin and Streptomycin (Invitrogen Ltd, Paisley,
UK). For measurement of lymphoproliferative responses
PBMCs were labelled with 5, 6-carboxyfluorescien diace-
tate succinimdyl ester (CFSE; Invitrogen Ltd, Paisley, UK)
according to manufacturer’s protocols. CFSE-labelled cells
were incubated in 96-well, U bottom culture plate
(Thermo Fisher Scientific, Loughborough, UK) at a density
of 2x105 cell per well in triplicate. PBMCs were stimulated
with 20mer HIV-1 envelope peptides with a 10 amino acid
overlap (CFAR, NIBSC, UK) at a concentration of 1 μg/ml/
peptide for pools and at 5 μg/ml for single peptides
(Table 7). Cultures were maintained at 37°C in a 5% CO2
incubator for 5 days. To confirm the phenotype of prolifer-
ating cells PBMC were labelled with APC-Cy7 conjugated
monoclonal anti-CD4 (Biolegend Ltd, Cambridge, UK) for
20 min at room temperature. Samples were analyzed on
FACS CantoII (Becton Dickinson, Oxford, UK). From each
sample a minimum of 100,000 events was collected and
analysed using FACSDiva software. Proliferation was
reported as the percentage of cells that had undergone 2 or
more rounds of cell division.
Statistical analysis
For comparison of peptide pools one-way ANOVA with
Bonferroni’s multiple comparison test was employed to as-
sess differences between responses to W61D, IIIB and SF33.
For comparison of responses to single peptides a Mann–
Whitney U test was employed to assess differences between
W61D/IIIB and SF33. P values <0.05 were considered sig-
nificant (*), <0.005 highly significant (**) and <0.0001 very
significant (***) using the Graph Pad Prism 5 software.
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